Case 2: Frontline Treatment Data in Stage IV NSCLC

2020 Evolution | Lung Cancer Case PresentationПодробнее

Case 2: Frontline Decisions in Stage IV BRAF-mutant MelanomaПодробнее

Case 3: Considerations for Second-Line Therapy in Stage IV NSCLCПодробнее

Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy UseПодробнее

Case 3: Rapidly Progressing Stage IV NSCLC Following Immuno-ChemotherapyПодробнее

Treatment of Stage IV NSCLC with High PD-L1 and Atypical Mutation - Lung Cancer OncTalk 2022Подробнее

Case 2: Treatment Considerations in Stage IV NSCLCПодробнее

Case 2: Frontline Therapy in EGFR-Mutated Lung CancerПодробнее

Case 2: Biomarkers and Treatment Decisions in Stage IV NSCLCПодробнее

Frontline Therapy Approaches for Small Cell Lung CancerПодробнее

When Should I Combine Checkpoint Inhibitors & Chemotherapy in Frontline Treatment of Advanced NSCLC?Подробнее

Case 4: Treating Stage IV NSCLC With Novel ApproachesПодробнее

The role of Immunotherapy in stage IV NSCLC (PDL1 high/low)Dr. Julian Molina Day 2Подробнее

2020 CBPD LEVY - Stage IV NSCLC ALK Positive 74 YO Male with Brain MetastasisПодробнее

Full Event Mainstage 2023 Targeted Therapies in Lung Cancer Patient Forum ON-DEMANDПодробнее

Facilitating Progress in the Treatment of SCLCПодробнее

Case Discussion: A 65-year-old Man with Stage IV NSCLC_old2Подробнее

Approaching Non-Driver Stage IV NSCLCПодробнее

Case-based clinical update in Lung Cancer | 2023 Community Cases MemphisПодробнее